RxDoctor Payments Data

Natalia Pawlowski, MD

Family Medicine · Charleston, SCNPI 1114280377

Payments from drug & device makers

$4,879in general payments, 2019–2025

Across 207 payments — averaging $23.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • TG Therapeutics, Inc.$664
  • AbbVie$626
  • Novo Nordisk$560
  • Pfizer$458
  • Lilly USA, LLC$405
  • Gilead$256
  • plus $2K from 26 others

What the payments were for

  • Travel & lodging$66414%
  • Food & beverage$4,21686%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,879 in reported general payments places this provider in the 85th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$141,731
Medicare patients
376
Services billed
1,648

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide108$190,026
EliquisApixaban71$96,807
RybelsusSemaglutide25$58,066
FarxigaDapagliflozin Propanediol39$49,761
MounjaroTirzepatide30$49,351
JardianceEmpagliflozin40$43,653
TrulicityDulaglutide17$36,633
XareltoRivaroxaban24$28,163
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$21,573
JanuviaSitagliptin Phosphate16$20,695
Atorvastatin Calcium392$4,126
Rosuvastatin Calcium221$4,030
Albuterol Sulfate HfaAlbuterol Sulfate74$3,366
Estradiol14$3,026
Levothyroxine Sodium216$2,792

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$560$248,092133 claims
PfizerEliquis$458$96,80771 claims
Lilly USA, LLCMounjaro, Trulicity$405$85,98447 claims
AstraZenecaFarxiga$166$49,76139 claims
Boehringer IngelheimJardiance$75$43,65340 claims
Johnson & JohnsonXarelto$82$28,16324 claims
GSKTrelegy Ellipta$234$21,57319 claims
MerckJanuvia$94$20,69516 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$28$2,792216 claims
AbbVieSynthroid$626$2,41935 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →